What is the Historical Analysis of the Unresectable Hepatocellular Carcinoma Market Size?
The unresectable hepatocellular carcinoma market has seen considerable growth due to a variety of factors.
•The market size of unresectable hepatocellular carcinoma has seen a minor increase in its recent years. It is set to expand from $1.98 billion in 2024 to $2.01 billion in 2025, growing at a compound annual growth rate (CAGR) of 1.9%.
The factors contributing to this growth during the historic period include advancements in chemotherapy, results of clinical trials, restrictions in liver transplantation, an uptick in cancer instances, and wider access to treatment options.
What is the Forecasted Growth of the Unresectable Hepatocellular Carcinoma Market Size?
The unresectable hepatocellular carcinoma market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for unresectable hepatocellular carcinoma is poised for robust expansion in the forthcoming years, anticipated to reach a value of $2.95 billion in 2029, registering a compound annual growth rate (CAGR) of 10.0%.
This upward trend during the forecast period is projected to result from various factors including revisions in healthcare policies, execution of patient segmentation methods, application of real-world evidence, heightened patient advocacy and awareness, as well as economic dynamics. Key trends over the forecast horizon encompass precision medicine and biomarkers, integration of real-world evidence and data, interdisciplinary techniques, international clinical trials and partnerships, along with a focus on patient-centered care.
What Are The Primary Growth Drivers In The Unresectable Hepatocellular Carcinoma Market?
The escalating rates of liver cancer are propelling the expansion of the unresectable hepatocellular carcinoma market. Liver cancer involves the healthy cells of the liver being replaced by burgeoning tumor cells. Unresectable hepatocellular carcinoma, a form of this cancer, is managed via liver transplant and radiofrequency ablation methods. For example, the Journal of Hepatology, a Switzerland-based academic journal, reported in October 2022 that 830,200 individuals around the world passed away due to liver cancer by 2020. It is also expected that from 2020 to 2040 there will be around 1.4 million new diagnoses of liver cancer, which translates to a 55.0% increase in annual new cases. Furthermore, as per the American Cancer Society, a non-profit organization from the US, in January 2024, 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer are forecast in the U.S. in the same year, including 28,000 in men and 13,630 in women. Approximately 29,840 deaths are expected, with 19,120 in men and 10,720 in women. Hence, the rising incidence of liver cancer fuels the growth of the unresectable hepatocellular carcinoma market.
What Is The Segmentation Of The Global Unresectable Hepatocellular Carcinoma Market?
The unresectable hepatocellular carcinoma market covered in this report is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Pre-Book The Unresectable Hepatocellular Carcinoma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Unresectable Hepatocellular Carcinoma Market Landscape?
The introduction of groundbreaking products is an emerging trend within the impossible-to-remove liver cancer marketplace. Key players in this market are embracing such innovations to maintain their market dominance. Notably, AstraZeneca, a pharmaceutical and biotech company based in the UK, unveiled an FDA-approved combination of Imjudo (tremelimumab) and Imfinzi in the US for people suffering from non-surgical liver cancer in October 2022. The groundbreaking treatment model dubbed as the STRIDE regimen consists of a one-time dosage of the anti-CTLA-4 antibody Imjudo 300mg, combined with the anti-PD-L1 antibody Imfinzi 1500 mg given in four-week intervals. When patients were treated with both Imjudo and Imfinzi, they exhibited a 22% less likelihood of mortality than those treated with sorafenib.
Who Are the Key Players in the Unresectable Hepatocellular Carcinoma Market?
Major companies operating in the unresectable hepatocellular carcinoma market include:
• Pfizer Inc.
• Johnson & Johnson Private Limited
• F Hoffmann-La Roche Ltd.
• Merck & Co Inc.
• Bayer AG
• Bristol-Myers-Squibb Company
• Astrazeneca PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Chugai Pharmaceutical Co Ltd.
• Eisai Co. Ltd.
• Ipsen S.A.
• Jiangsu HengRui Medicine Co. Ltd.
• Exelixis Inc.
• BeiGene Ltd.
• Halozyme Therapeutics Inc.
• Innovent Biologics Inc.
• Sirtex Medical Limited
• Blueprint Medicines Corporation
• Genentech Inc.
• CStone Pharmaceuticals
• Pharmicell Co. Ltd.
• Pharmaxis Ltd.
• Delcath Systems Inc.
• Yiviva Inc.
• Celsion Corporation
• Mendus AB.
What are the Regional Insights into the Unresectable Hepatocellular Carcinoma Market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
